Head & Neck Cancers

Pembrolizumab plus concurrent chemoradiation followed by pembrolizumab maintenance did not lead to a statistically significant improvement in event-free survival vs concurrent chemoradiation alone in patients with unresected locally advanced head and neck squamous cell carcinoma.

Cabozantinib monotherapy maintained continued to provide a superior progression-free survival benefit to that achieved with placebo in adults with locally advanced or metastatic differentiated thyroid carcinoma, irrespective of histology, according to updated data from the phase 3 COSMIC-311 trial.

The phase 2 CP-MGA271-06 trial closed early following an internal review of safety data of enoblituzumab plus retifanlimab or tebotelimab as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

The FDA has accepted for review a biologics license application resubmission for toripalimab both in combination and as monotherapy for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, according to an announcement from drug developer Coherus.

The FDA has granted a fast track designation to PDS0101 for use in combination with pembrolizumab in patients with recurrent or metastatic HPV16-positive head and neck cancer.

Tislelizumab plus chemotherapy continued to improve progression-free survival over chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated data from the RATIONALE-309 trial.

The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.

Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Avasopasem significantly reduced severe oral mucositis across all intensity-modulated radiotherapy landmarks in patients with locally advanced, nonmetastatic head and neck cancer.

In the context of checkpoint blockade in nasopharyngeal carcinoma, the results of the phase 3 RATIONALE-309 trial support earlier findings of the role immunotherapy may play for patients in the first line.

Experts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.

Before closing out their discussion on radioiodine-refractory DTC management, experts share practical advice for community physicians.

Shared insight on active surveillance practices for patients with radioiodine-refractory DTC and how disease factors play into selection of therapy at time of recurrence.

Reflecting on a real-world patient scenario of DTC, experts consider how they identify radioiodine-refractory disease and when they would initiate systemic therapy.

Expert Lori Wirth, MD, highlights key points from a second real-world patient scenario of radioiodine-refractory differentiated thyroid cancer.

Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.

The European Commission has approved the use of cabozantinib for use as a single agent in adult patients with locally advanced or metastatic differentiated thyroid carcinoma who are refractory or not eligible to receive radioactive iodine and who have progressed during or following previous systemic treatment.

The FDA is seeking the approval of toripalimab plus gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma and for use as a monotherapy in the second-line and later treatment of those with recurrent or metastatic disease.

Expert advice on addressing adverse events, particularly through dose holds or reduction, in patients on lenvatinib therapy for radioiodine-refractory DTC.

Shared insight on selecting appropriate patients for lenvatinib therapy in differentiated thyroid cancer, as well as optimizing dosing strategies in the context of clinical trial data.

A brief discussion on where endocrinologists and oncologists respectively fit into the differentiated thyroid cancer treatment paradigm.

Reflecting on the first patient scenario of radioiodine-refractory DTC, experts share their considerations for optimally selecting and sequencing therapy in this setting.

The combination of tislelizumab and gemcitabine/cisplatin continued to demonstrate a greater progression-free survival benefit than chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.